Argenx Se (ARGX) has released an update.
Argenx SE’s groundbreaking ADHERE study, published in The Lancet Neurology, showcases the effectiveness of VYVGART Hytrulo in treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare neuromuscular disorder. This largest clinical trial of its kind demonstrated a 61% reduction in disease relapse risk and marked improvements in patient mobility and strength. VYVGART Hytrulo is also recognized as the only FDA-approved neonatal Fc receptor blocker, affirming its innovative impact on CIDP treatment.
For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.
